ORCID as entered in ROS

Select Publications
2024, 'An open-label safety and feasibility pilot trial of ketamine-assisted psychotherapy for methamphetamine use disorder', Canberra, Australia, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'Exploring the perceived usefulness of integration support after naturalistic psychedelic experiences in people concerned about their substance use: a survey', Wesley Conference Centre, Sydney NSW, presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024
,2022, 'The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study', Minneapolis, USA, presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 June 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2021, 'A clinical research network approach to a trial of lisdexamfetamine for the treatment of acute methamphetamine withdrawal', Virtual, Vol. 40, pp. S132 - S133, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,2021, 'Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials', Virtual, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,